Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating an artificial intelligence system to assist in classifying how deeply early esophageal squamous cell carcinoma invades tissue using endoscopic ultrasound. This helps provide a basis for preoperative T staging and supports diagnosis and treatment decisions. The study is a multicenter, prospective, randomized cohort trial, comparing AI-assisted grading to routine diagnosis methods in patients with early esophageal cancer or precancerous lesions. Participants will be randomly assigned to one of two groups the AI group, which uses artificial intelligence to assist in determining the invasion depth under endoscopic ultrasound, or the control group, which receives routine diagnosis without AI assistance. Each group is expected to include about 100 patients. The study uses central randomization with single masking, where the procedure is identified as protocol A or B by the operating physician based on allocation. During the study, researchers will assess the accuracy of grading the depth of cancer invasion over two years. They will also monitor secondary outcomes such as survival rate over three years and progression-free survival over one year. Participants undergo endoscopic ultrasound and pathological examinations, with detailed records reviewed. The study will last several years, ensuring thorough evaluation and follow-up to understand the impact of AI-assisted diagnosis on early esophageal cancer staging.
Actively Recruiting
Researchers are evaluating the pain relief effects of wrist-ankle acupuncture in patients experiencing different types of pain after perianal surgery. This prospective clinical observation involves 60 patients aged 18 to 75 years who have postoperative pain with a Visual Analog Scale VAS score of 4 or higher. The study also aims to explore how postoperative pain influences the occurrence of urinary retention. Patients are divided into two groups based on their pain type sphincter spasm pain and acute incisional pain. All patients receive routine postoperative care including intravenous flurbiprofen infusion, herbal sitz baths, and pain education. Wrist-ankle acupuncture is given once daily when the pain score reaches 4 or higher, involving superficial needle insertion at specific zones on both lower limbs. Needles are kept in place for 0.5 to 1 hour, and treatment duration is adjusted based on symptom improvement. If pain remains high 30 minutes after acupuncture, additional analgesic medication is provided. During the study, researchers monitor pain scores before and after acupuncture, the frequency of pain medication use within three days post-surgery, and urinary retention scores 24 hours after surgery. Participants will be observed throughout their hospital stay to assess these outcomes and the overall effect of wrist-ankle acupuncture on postoperative pain and urinary retention.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of neoadjuvant adebrelimab combined with chemotherapy in patients diagnosed with locally advanced esophageal squamous cell carcinoma ESCC. This exploratory, single-arm Phase 2 clinical study aims to understand how well this combination works before surgery in this patient group. The study is being conducted by The Affiliated Hospital of Putian University and focuses on patients with confirmed ESCC at specific clinical stages who have not yet received prior anti-tumor treatments. Participants will receive adebrelimab at a dose of 1200 mg or 20 mgkg through intravenous infusion every three weeks. They will also receive chemotherapy consisting of nanoparticle albumin-bound paclitaxel Nab-paclitaxel 100 mgm on days 1 and 8, and cisplatin 75 mgm on days 1, 2, and 3, both administered every three weeks. This neoadjuvant treatment is given before planned surgical resection, and patients are predicted to be eligible for R0 resection, which aims for complete tumor removal. During the study, participants will be closely monitored through various assessments including pathological complete response rate four weeks after surgery, surgical resection success, disease-free survival, overall survival, and response rates up to three months. Safety will be tracked by recording adverse events for up to two years. The total participation time includes neoadjuvant treatment, surgery, and follow-up assessments extending to 24 months to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are investigating a new treatment approach for patients with HER2-positive muscle-invasive bladder cancer MIBC staged cT2-4aN0-1M0. This phase II, multicenter, open-label study evaluates combining zanidatamab and tislelizumab with chemotherapy before surgery, aiming to preserve the bladder selectively. The study focuses on assessing the treatments effectiveness and safety in this specific patient group. Participants receive neoadjuvant therapy consisting of zanidatamab, tislelizumab, and chemotherapy drugs such as cisplatin, gemcitabine, or nab-paclitaxel over four cycles, each lasting 21 days. After these initial treatments, patients are reassessed for clinical complete response cCR. Those achieving cCR continue maintenance therapy with zanidatamab and tislelizumab, while others may undergo radiotherapy or partial cystectomy followed by maintenance therapy or proceed directly to radical cystectomy with adjuvant tislelizumab. Throughout the trial, participants undergo regular evaluations including tumor assessments and safety monitoring. The main outcome is the rate of clinical complete response at the end of neoadjuvant therapy. Secondary outcomes include disease-free survival rates, recurrence-free survival, overall survival, safety, and quality of life measures over up to three years. The study aims to understand how well this treatment strategy can preserve the bladder and improve patient outcomes.
Actively Recruiting
Researchers are evaluating normobaric hyperoxia NBO as a treatment for patients who have experienced an acute ischemic stroke and are transferred for endovascular thrombectomy EVT. The study aims to assess the effectiveness and safety of NBO in improving functional outcomes at 3 months after stroke. Stroke is a leading cause of death and disability, and although reperfusion treatments like thrombectomy improve blood flow, less than half of patients achieve favorable recovery. NBO is thought to protect the brain by rescuing hypoxic tissue and reducing damage processes, with advantages such as low cost and easy use. Participants will be randomly assigned to receive either NBO, which involves inhaling 100% oxygen alongside the best medical care, or best medical care alone. The study compares these two groups to see if NBO provides additional benefits. The treatment is given during the acute phase before or during transfer for EVT. The study includes a single-blind design and follows patients for outcomes over time. During the study, participants will have their disability level measured using the modified Rankin Scale at 90 days and one year after randomization. Other assessments include neurological function scores, imaging scans, infarct volume changes, and quality of life questionnaires at various time points. Safety and recovery progress are closely monitored throughout, with follow-up visits to track long-term effects. The total participation duration includes initial treatment and follow-up through one year.
Actively Recruiting
Researchers are studying the prevalence of chronic obstructive pulmonary disease COPD among participants aged 40 years or older who have one of three types of cardiovascular diseases coronary heart disease, atrial fibrillation, or chronic heart failure. This multi-center, prospective, interventional study aims to understand how cardiopulmonary co-management affects the short-term health outcomes of participants with both cardiovascular disease and COPD. Approximately 3,000 participants will be enrolled, with about 1,000 in each disease cohort. The study intervention includes guideline education and implementation at both the investigator and patient levels. Investigators receive education on COPD and cardiovascular disease about four weeks before enrolling participants. After enrollment, cardiologists and pulmonologists provide disease education every four weeks, along with collaborative treatment management for participants with both conditions. Participants are followed up every four weeks throughout the study. During the study, participants will undergo spirometry testing, complete questionnaires, and have various health measures recorded, including hospitalization rates and scores related to heart and lung function. Researchers will also monitor lung function tests, blood markers, and medication use at baseline and at weeks 4, 8, and 12. The primary outcome is the number and percentage of participants with COPD across the cardiovascular disease cohorts. The study includes short-term follow-up over 12 weeks to observe treatment and health changes.